GHK-Cu and KPV research often appears in the same skincare conversation, although the compounds and the evidence behind them differ. Understanding what was tested is more useful than treating the word peptide as a promise of healthier skin.
GHK-Cu: a copper peptide studied in the laboratory
GHK-Cu is a copper-binding tripeptide. A study by Maquart and colleagues reported an effect on collagen synthesis in fibroblast cultures. That is a laboratory finding, not a clinical result for every cream, serum or pen containing the ingredient.
Searches for GHK-Cu topical products and GHK-Cu injections describe different routes of exposure. Evidence for one formulation or route cannot establish the safety or effectiveness of another.
KPV: keep the study model in view
Dalmasso and colleagues investigated KPV in cell experiments and mouse models of intestinal inflammation. This is a useful example of why a biological research finding should not be rewritten as an established skincare benefit in people.
Check the actual product ingredients
The current Svelta Labs Glow Pen listing identifies GHK-Cu, BPC-157 and TB-500. It does not list KPV. An article discussing KPV must not imply that it is an ingredient in that product or that Svelta currently sells a separate KPV item.
Use the GHK-Cu research profile to explore terminology, then check the original study, study population and formulation behind a claim. Clear product education should help readers recognise these boundaries without making human treatment promises.
Sources: Maquart et al., FEBS Letters, 1988, PMID 3169264; Dalmasso et al., Gastroenterology, 2008, PMID 18061177. Further Svelta education is available at Svelta Labs.
Sources
Maquart et al., GHK-Cu primary study: https://pubmed.ncbi.nlm.nih.gov/3169264/
Dalmasso et al., KPV primary study: https://pubmed.ncbi.nlm.nih.gov/18061177/